Publications by authors named "Mingtao Shi"
Article Synopsis
- Glioblastoma (GBM) is a highly aggressive brain tumor with low survival rates, prompting research into targeted therapies like a combination of nimotuzumab, bevacizumab, radiotherapy, and temozolomide.
- A study conducted on 18 GBM patients showed promising results with a one-year progression-free survival rate of 77.8% and an overall survival rate of 94.4% over a median follow-up of 23 months.
- The treatment was found to be effective and safe, with manageable adverse events, although further studies are necessary to validate these findings.
Cervical cancer is one of the most common malignant tumors in women, and more than one-third of the patients have already developed to a locally advanced stage at initial diagnosis. After standard concurrent chemoradiotherapy, recurrence still occurs in 29-38% of patients with locally advanced cervical cancer (LACC), and the 5-year survival rate of patients with recurrence is only 3.8-13.
View Article and Find Full Text PDF